COMPANY

Eledon Pharmaceuticals

HQ: Irvine, CA source · eledon.com ↗ · West Coast

Eledon Pharmaceuticals develops tegoprubart, a product candidate based on CD40 Ligand biology. Eledon Pharmaceuticals is conducting clinical research on tegoprubart in kidney transplantation, islet cell transplantation and xenotransplantation. From company website Source · checked 2026-10-19

Eledon Pharmaceuticals is listed on ClinicalTrials.gov as the lead sponsor of 6 studies; the most recently updated is “Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation” (Phase 3, not yet recruiting), in Kidney Transplant Rejection. From public records Source · 2026-10-12

Sources for this description (2)

Eledon Pharmaceuticals develops tegoprubart, a product candidate based on CD40 Ligand biology.
- “Our focus on and deep understanding of the biology and Mechanism of Action of the CD40 Ligand have driven Eledon’s research and development of our lead product candidate tegoprubart.” https://eledon.com/science/pipeline/ (2026-10-19)
Eledon Pharmaceuticals is conducting clinical research on tegoprubart in kidney transplantation, islet cell transplantation and xenotransplantation.
- “Eledon is currently conducting clinical research on the potential benefits of treatment with tegoprubart in kidney transplantation, islet cell transplantation and xenotransplantation.” https://eledon.com/science/pipeline/ (2026-10-19)

Target: CD40 Ligand

Keywords: xenotransplantation neurology immunology neurodegenerative diseases Kidney Transplant Rejection Prevention of Rejection in Kidney Transplant IgA Nephropathy IgAN Brittle Type 1 Diabetes Mellitus AT-1501

Location: Irvine, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$135.0MRaised (2 yrs)6Trials (company is sponsor)

Timeline

2026-10 Trial start Phase 3: Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation source ↗
Nov 12, 2025 Raise Follow-on offering: $50M (total, as published), announced Nov 12, 2025. Source: company release on GlobeNewswire. source ↗
Oct 29, 2024 Raise Follow-on offering: $85M (total, as published), announced Oct 29, 2024. Source: SEC filing. source ↗
Oct 25, 2023 Trial start Phase 2: Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients source ↗
Aug 30, 2023 Trial start Phase 2: Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation source ↗
Sep 30, 2022 Trial start Phase 1/Phase 2: Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D source ↗
Mar 21, 2022 Trial start Phase 2: Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN) source ↗
Feb 18, 2022 Trial start Phase 1/Phase 2: Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant source ↗

Upcoming milestones

2027-01 (ESTIMATED) · Phase 1/Phase 2 · Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant · NCT05027906
2029-03 (ESTIMATED) · Phase 3 · Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation · NCT07835581
2029-12 (ESTIMATED) · Phase 2 · Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients · NCT06126380

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $135.0M. Last 2 years.

Nov 12, 2025 Follow-on offering: $50M (total, as published), announced Nov 12, 2025. Source: company release on GlobeNewswire. source ↗
Oct 29, 2024 Follow-on offering: $85M (total, as published), announced Oct 29, 2024. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT07835581	Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation	Phase 3	Not yet recruiting	2026-10	2029-03 (estimated)
NCT05983770	Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation	Phase 2	Completed	Aug 30, 2023	Sep 11, 2025 (actual)
NCT06126380	Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients	Phase 2	Enrolling by invitation	Oct 25, 2023	2029-12 (estimated)
NCT05027906	Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant	Phase 1/Phase 2	Recruiting	Feb 18, 2022	2027-01 (estimated)
NCT05125068	Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)	Phase 2	Terminated	Mar 21, 2022	Jul 31, 2023 (actual)
NCT05480657	Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D	Phase 1/Phase 2	Withdrawn	Sep 30, 2022	2024-08 (estimated)